CLINICAL_TRIALS
trial_result
· 2024-04-01
Clinical Trial Update: Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients [Phase 1, Phase 2]
Summary
Phase 1/2 study of isatuximab as a single agent in Japanese relapsed and refractory multiple myeloma completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sanofi | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-04-01